Glucagon-like peptide-2 analogue, its preparation method and application

A technique for glucagon and analogs, applied in the field of glucagon-like peptide-2 analogs and their preparation and use, can solve the problems of inconclusive GLP-2 intestinal tumor and the like

Inactive Publication Date: 2013-02-27
JIANGSU HANSOH PHARMA CO LTD
View PDF10 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been confirmed that GLP-2 has the effect of promoting nutrient absorption, but whether it can reduce intestinal damage and promote intestinal repair has yet to be confirmed by further clinical trials
Although the adverse effects of GLP-2 have not been found during the treatment, considering that the biological role of GLP-2 was found in the study of glucagon-induced tumors in animals, and the study of subcutaneous injection of glucagon in nude mice It has been shown that GLP-2 significantly promotes the growth of intestinal mucosa, so whether GLP-2 stimulates the growth of intestinal tumors is still inconclusive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glucagon-like peptide-2 analogue, its preparation method and application
  • Glucagon-like peptide-2 analogue, its preparation method and application
  • Glucagon-like peptide-2 analogue, its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1 Solid-phase synthesis of positive compound Teduglutide

[0055] The sequence of the positive compound Teduglutide is:

[0056] H-His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn- Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-OH

[0057] (1) Drying and swelling of solid-phase synthetic resin

[0058] Weigh 40g (20mmol) of Fmoc-Asp(OtBu)-Wang resin (0.5mmol / g) dried in vacuum for 24 hours and place it in a 2L bubbling bottle, add 400mL of DMF swelling resin for 30 minutes, and remove the DMF solution;

[0059] (2) Fmoc-Asp(OtBu)-Wang resin to remove Fmoc protecting group

[0060] 200 mL of 20% piperidine / DMF solution was added to the bubbling bottle containing Fmoc-Asp(OtBu)-Wang resin, and the solution was drawn out after 5 minutes of reaction, and then 200 mL of 20% piperidine / DMF solution was added to react at room temperature for 20 minutes. After the reaction was completed, the resin was washed four times with 200 mL...

Embodiment 2

[0072] Example 2 Solid-phase synthesis of compound 1

[0073] The sequence of compound 1 is:

[0074] D-His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn- Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-OH, that is, in the general formula (I), X1 is D-His, X2 is Gly, X3 is ASP, X10 is Met, and X11 is Asn , X15 is Asp, X16 is Asn, X24 is Asn, and X25 is Trp.

[0075] The preparation method is the same as in Example 1.

Embodiment 3

[0076] Example 3 Solid-phase synthesis of compound 2

[0077] The sequence of compound 2 is:

[0078]D-His-Gly-Glu-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn- Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-OH, that is, in the general formula (I), X1 is D-His, X2 is Gly, X3 is Glu, X10 is Met, and X11 is Asn , X15 is Asp, X16 is Asn, X24 is Asn, and X25 is Trp.

[0079] The preparation method is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a glucagon-like peptide-2 analogue, its preparation method and application. The invention relates to a glucagon-like peptide-2 (GLP-2) analogue and its medical application. The invention further relates to a medicine composition containing the GLP-2 analogue and its medicinal salts. According to the invention, the GLP-2 analogue or the medicine composition containing the GLP-2 analogue and its medicinal salts can be widely applied for preventing or treating mucosal injury-related gastrointestinal symptoms and mitigating the side effects on gastrointestinal tract caused by chemotherapy and radiation therapy.

Description

[0001] This application is a divisional application of a Chinese patent application with the application number of 200910126363.9 and the filing date of March 5, 2009, and the invention title is "Glucagon-like peptide-2 analogs and their preparation methods and uses". technical field [0002] The present invention relates to a glucagon-like peptide-2 (Glucagon Like Peptide-2, GLP-2) analog and its preparation for preventing and / or treating gastrointestinal mucosal damage-related disorders and alleviating chemotherapy and radiotherapy. Use in medicine for intestinal side effects. Background technique [0003] GLP-2 belongs to proglucagon-derived peptide (PGDP), which is one of the degradation products of proglucagon (PG) by prohormone convertase (PC). A single-chain polypeptide consisting of 33 amino acid residues with a molecular weight of 3900 Daltons, its amino acid sequence is highly conserved in mammals [Drucker DJ.Glucagon-like peptide 2.J Clin Endocrinol Metab, 2001, 8...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/605C07K1/20C07K1/04A61K38/26A61P1/04
CPCA61K38/26A61P1/00A61P1/04A61P1/08A61P1/12A61P1/14A61P19/10A61P35/00C07K14/605
Inventor 王亚里孙长安王瑞军姜涛
Owner JIANGSU HANSOH PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap